Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
• Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² • Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² • CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an ...